A Study of PHST001 in Advanced Solid Tumors
NCT06840886
This study is recruiting at 20 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumors
- Ovarian Cancer
- Endometrial Cancer
- Cholangiocarcinoma
- CNS Tumor
- Breast Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma
- Carcinosarcoma, Ovarian
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Pheast Therapeutics
- Last updated on ClinicalTrials.gov
- October 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- Precision NextGen Oncology & Research Center · Beverly Hills, CA
- USC Norris Comprehensive Cancer Center · Los Angeles, CA
- Stanford University School of Medicine · Palo Alto, CA
Colorado · 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One · Denver, CO
Connecticut · 1
- Yale Cancer Center · New Haven, CT
Illinois · 1
- University of Chicago Medical Center · Chicago, IL
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
Michigan · 2
- University of Michigan Rogel Cancer Center · Ann Arbor, MI
- START Center for Cancer Research - Midwest · Grand Rapids, MI
New York · 2
- START Center for Cancer Research - Long Island New York · Lake Success, NY
- Mount Sinai · New York, NY
North Carolina · 1
- Duke Cancer Institute · Durham, NC
Tennessee · 2
- Sarah Cannon Research Institute (SCRI) Oncology Partners · Nashville, TN
- Vanderbilt-Ingram Cancer Center · Nashville, TN
Texas · 5
- START Center for Cancer Research - Texas · Fort Worth, TX
- MD Anderson Cancer Center · Houston, TX
- NEXT Oncology - Dallas · Irving, TX
- START Center for Cancer Research - San Antonio · San Antonio, TX
- University of Texas (UT) Health · San Antonio, TX
Virginia · 1
- NEXT Oncology - Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.